

Sun Pharmaceutical Industries Ltd.,  
SUN HOUSE, CTS No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai 400063, India  
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343  
CIN: L24230GJ1993PLC019050  
www.sunpharma.com



**11 May 2018.**

National Stock Exchange of India Ltd,  
Exchange Plaza, 5th Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East),  
Mumbai – 400 051.

BSE Limited,  
Market Operations Dept.  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001.

Dear Sirs,

**Sub: Press Release**

We are pleased to enclose herewith our Press Release relating to announcement of financial results for the fourth quarter ending March 31, 2018, which we shall be releasing after sending this letter to you. This is for your information and record.

Thanking you,

Yours faithfully,  
For Sun Pharmaceutical Industries Ltd

Ashok I. Bhuta  
Compliance Officer

Encl: as above

**FOR IMMEDIATE RELEASE**

**Sun Pharma to announce fourth quarter results on May 25, 2018**

May 11, 2018, Mumbai: Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) will announce results for the fourth quarter & full year ending March 31, 2018 on May 25, 2018. These results will also be available on the Company website, [www.sunpharma.com](http://www.sunpharma.com).

**Earnings call (06.30 pm IST, May 25, 2018)**

The Company will conduct an hour long call at 06.30 pm IST on May 25, 2018 where senior management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below, five to ten minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call. You can also hear the call via an audio webcast, details of which will be announced later on the Company website, [www.sunpharma.com](http://www.sunpharma.com). A transcript of this conference call will also be available on the website.

**Summary of events**

<b>Event</b>	<b>Date and time</b>	<b>Telephone number/ website</b>
Earnings release	May 25, 2018	<a href="http://www.sunpharma.com">www.sunpharma.com</a>
Earnings conference call	06.30 pm IST, May, 25, 2018	Primary Number : +91 22 6280 1278  Via audio webcast, details of which will be made available on <a href="http://www.sunpharma.com">www.sunpharma.com</a>
Replay of conference call	May 25, 2018 to June 01, 2018	India: +91 22 7194 5757  Code: 25282  Via audio webcast playback, details of which will be made available on <a href="http://www.sunpharma.com">www.sunpharma.com</a>

Sun Pharmaceutical Industries Ltd.  
SUN HOUSE, CTS No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai 400063, India  
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343  
CIN: L24230GJ1993PLC019050  
[www.sunpharma.com](http://www.sunpharma.com)



#### **Disclaimer:**

Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied.

#### **About Sun Pharmaceutical Industries Ltd. (CIN - L24230GJ1993PLC019050):**

Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world. Sun Pharma's global presence is supported by 41 manufacturing facilities spread across 6 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. In India, the company enjoys leadership across 12 different classes of doctors with 32 brands featuring amongst top 300 pharmaceutical brands in India. Its footprint across emerging markets covers over 100 markets and 6 markets in Western Europe. Its Global Consumer Healthcare business is ranked amongst Top 10 across 3 global markets. Its API business footprint is strengthened through 14 world class API manufacturing facilities across the globe. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising about 2,000 scientists and R&D investments of approximately 8% of annual revenues. For further information, please visit [www.sunpharma.com](http://www.sunpharma.com) & follow us on Twitter @SunPharma\_Live.

#### **Contacts**

Nimish Desai  
Tel +91 22 4324 4324, Xtn 2778  
Tel Direct +91 22 4324 2778  
Mobile +91-98203 30182  
E mail [nimish.desai@sunpharma.com](mailto:nimish.desai@sunpharma.com)

Gaurav Chugh  
Tel +91 22 4324 4324, Xtn 5373  
Tel Direct +91 22 4324 5373  
Mobile +91 98104 71414  
E mail [Gaurav.chugh@sunpharma.com](mailto:Gaurav.chugh@sunpharma.com)